CIK 0001498382
- Non-accelerated filer
- Smaller reporting company
TuHURA Biosciences, Inc./NV
Sign in to watch- Ticker
- HURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 990360497
- Phone
- +1 813-875-6600
- Business address
- 10500 UNIVERSITY CENTER DR., SUITE 110, TAMPA, FL, 33612
- Former names
- Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc., Berry Only Inc.
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy CEO and President bought 7,500 shares at an average $0.66 ($4,925)
- 4 Open-market buy CEO and President bought 2,500 shares at $0.90 ($2,250)
- 4 Open-market buy CEO and President bought 2,500 shares at $0.92 ($2,300)
- 4 Open-market buy Director bought 8,000 shares at $0.95 ($7,600)
- 4/A Derivatives Options or other derivatives
- 3/A Insider 3/A
- 4 Conversion Director acquired 2,388,541 shares (conversion)
- 4 Other acquisition Chief Scientific Officer acquired 278,530 shares (other)
- 4 Open-market buy CEO and President bought 4,000 shares at $0.98 ($3,920)
- 3/A Insider 3/A
- 4 Open-market buy CEO and President bought 4,985 shares at $0.75 ($3,739)
- 4 Open-market buy Director bought 7,000 shares at $0.71 ($4,970)
- 4 Open-market buy Director bought 8,000 shares at $0.78 ($6,237)
- 4 Open-market buy Director bought 20,000 shares at $1.25 ($25,000)
- 4 Open-market buy CEO and President bought 10,000 shares at $1.30 ($13,000)
- 4 Open-market buy Director bought 25,000 shares at $1.30 ($32,500)
- 4 Open-market sale Director sold 80,000 shares at $1.30 ($104,000)
- 4 Open-market buy Director bought 25,000 shares at $1.30 ($32,500)
- 4 Open-market buy CFO bought 10,000 shares at $1.30 ($13,000)
Page 14 of 16 · 308 filings